LTC Properties Inc vs Recursion Pharmaceuticals Inc — how do they compare? LTC Properties Inc trades at $38.43 (market cap $2.05B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: LTC Properties Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and LTC Properties Inc pays a 5.98% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| LTC | RXRX | |
|---|---|---|
Market Cap | $2.05B | $1.81B |
Sector | Real Estate | Health |
52-Week High | $42.81 | $6.79 |
52-Week Low | $33.98 | $2.84 |
Enterprise Value | $2.79B | $1.33B |
Dividend Yield | 5.98% | — |
Signals from Pluang's Aura AI — not financial advice
LTC Properties (LTC) trades at $38.32, down 2.79% over 24 hours, with a bullish technical signal driven by moving averages. The REIT shows strong profitability with a 61.72% gross margin and 38.93% net margin, though recent earnings missed estimates in two of the last three quarters. Recent news highlights aggressive expansion in seniors housing acquisitions, including a $95 million SHOP purchase announced August 5, 2026.
Outlook is mixed: demographic trends support long-term demand, but execution risks from rapid growth and debt-funded investments pose challenges. Analysts are cautious with 59% hold ratings, reflecting concerns over earnings consistency amid high capital expenditures.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Trailing returns across standard periods
Latest headlines on both assets
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →